Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample

Jones and colleagues situate the study within renewed clinical and research interest in MDMA (ecstasy), noting its empathogenic effects, acute physiological effects (for example increased heart rate and blood pressure), and recent promise as an adjunct to psychotherapy for treatment-resistant post-traumatic stress disorder. Earlier population-based work has reported protective associations between classic psychedelic use and several markers of physical health, and some observational and clinical reports suggest MDMA-assisted therapy can reduce comorbid conditions that influence physical health. Despite these threads, the authors identify a gap: few studies have examined associations between ecstasy use and broad markers of physical health in population-representative samples. This study therefore aimed to test whether lifetime ecstasy use is associated with a range of self-reported physical health markers in a nationally representative U.S. survey. Specifically, the investigators sought to replicate and extend prior findings on classic psychedelics by examining relationships between lifetime ecstasy use and body mass index (BMI), overall self-rated health, and several past-year cardiometabolic and disease outcomes.

The investigators used pooled data from the National Survey on Drug Use and Health (NSDUH). Two analytic blocks were used because the survey-year availability of variables differed: 2015–2018 data were pooled to analyse self-reported BMI, self-rated overall health, and a composite indicator of past-year heart condition and/or cancer; 2005–2014 data were pooled to analyse past-year heart disease, diabetes, and hypertension. Data were weighted to reflect the civilian non-institutionalised U.S. population; active duty military and people in institutional group quarters were not surveyed. Minors (17 years or younger) were excluded from analyses. Dependent variables included three ordered categories for BMI and self-rated overall health and several binary past-year disease indicators. Key dependent measures were: - BMI recoded to NIH categories from underweight to Extreme Obesity (Class 3 >40); - Self-reported overall health recoded from Fair/Poor to Excellent; - Binary past-year outcomes: heart condition and/or cancer (composite), heart disease, hypertension, and diabetes. Lifetime ecstasy use was the primary independent variable and was coded dichotomously (ever used = 1, never = 0). The models adjusted for an extensive set of covariates intended to control for sociodemographic and other substance-use confounders, including age, sex, sexual orientation (when available), ethnoracial identity, educational attainment, household income, marital status, a self-report of engagement in risky behaviour, lifetime classic psychedelic use (psilocybin, DMT, ayahuasca, LSD, mescaline/peyote/San Pedro), and lifetime use of a range of other substances (cocaine, other stimulants, sedatives, tranquilizers, heroin, pain relievers, marijuana, PCP, inhalants, various tobacco products and daily cigarette use), plus age of first alcohol use. Psychological distress was included as a control in the ordered logistic model for self-rated overall health. Statistical analysis used multinomial logistic regression for BMI, ordered logistic regression for self-rated overall health, and logistic regression for the binary disease outcomes. All models incorporated the NSDUH complex survey design and weights. Responses such as “don’t know” or “refused” were coded as missing except in the composite heart condition/cancer variable, which treated any affirmative response as positive. Analyses were conducted in Stata with an alpha threshold of 0.05 for statistical significance.

Jones and colleagues report that lifetime ecstasy use was associated with more favourable outcomes across several self-reported physical health markers after adjustment for the listed covariates. For BMI, lifetime ecstasy use was linked to a lower relative risk of being overweight or obese, with adjusted relative risk ratios reported in the range 0.55–0.88. In binary disease models, lifetime ecstasy use was associated with lower adjusted odds of reporting a past-year heart condition and/or cancer (adjusted odds ratio (aOR): 0.67), lower odds of past-year hypertension (aOR: 0.85), and lower odds of past-year diabetes (aOR: 0.58). By contrast, there was no significant association between lifetime ecstasy use and self-reported past-year heart disease. In the ordered logistic model, lifetime ecstasy use was associated with higher odds of reporting better overall health (aOR: 1.18). The authors also conducted post-hoc analyses separating the composite heart condition/cancer measure: these showed that lifetime ecstasy use was associated with a decreased likelihood of a self-reported past-year heart condition but was not associated with self-reported past-year cancer. The extracted text indicates these findings are presented in tabular form, but specific confidence intervals and p-values beyond the aORs and RRR range were not clearly reported in the extracted passages.

The investigators interpret the findings as establishing a preliminary cross-sectional association between lifetime ecstasy use and several markers of better self-reported physical health, and they note that these results replicate and extend earlier population-based findings linking classic psychedelic use to improved physical health markers. The authors emphasise the exploratory and non-causal nature of the evidence, stating that cross-sectional survey data cannot establish temporal precedence or causation but can motivate more rigorous experimental and longitudinal work. Several potential mechanisms are discussed. One possibility is post-use lifestyle change: ecstasy (and classic psychedelics) may catalyse psychological shifts that lead to healthier behaviours such as improved diet and greater physical activity. Second, the authors acknowledge potential uncontrolled confounding, including pre-existing personality or demographic differences between people who do and do not use ecstasy (for example higher extraversion among users), which could account for healthier lifestyles and thus the observed associations. Third, amelioration of mental health conditions—given evidence that MDMA-assisted therapy can reduce PTSD and possibly eating disorder or alcohol-use disorder symptoms—might indirectly produce downstream physical health benefits. Finally, an amphetamine-like appetite-suppressant effect of MDMA is noted as a speculative biological mechanism that could plausibly reduce the odds of obesity. The authors list several limitations they acknowledge in the paper. Chief among these is the cross-sectional design and the use of a binary lifetime-use measure, which precludes assessment of recency, frequency, dose, or temporal ordering. The NSDUH sampling frame excludes certain populations (active duty military, institutionalised individuals), limiting generalisability. Multicollinearity among many correlated covariates could have inflated standard errors, although the authors argue that large sample size partially mitigates this risk. Naturalistic ecstasy may be adulterated or variable in MDMA content, complicating attribution of associations to MDMA per se. The authors further caution that acute adverse cardiovascular effects of ecstasy have been documented, so the reported protective associations do not imply safety for all individuals or patterns of use. For future research, the investigators recommend longitudinal studies and clinical trials to probe causal pathways, suggest initial trials in healthy volunteers to examine potential lasting physical health effects, and propose investigation of ecstasy’s relationship to immune function and inflammation markers, while urging prudence given mixed prior findings on physiological harm. They conclude that these results are incremental and warrant further investigation rather than definitive claims about benefit.

Jones and colleagues conclude that, in this cross-sectional, nationally representative survey analysis, lifetime ecstasy use was associated with lower self-reported odds of overweightness and obesity, lower odds of a past-year heart condition and/or cancer, hypertension, and diabetes, and with higher odds of better self-rated overall health. They emphasise that these associations are not evidence of causation and call for longitudinal studies and clinical trials to determine whether the observed relationships reflect causal effects and to elucidate underlying mechanisms.